Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Celltrion’s COVID-19 treatment gets safety nod in Australia
By Kan Hyeong-wooPublished : Feb. 7, 2022 - 13:53
Celltrion has confirmed the safety of its inhalable antibody treatment for COVID-19 in a phase one clinical trial in Australia, the pharmaceutical company said Monday.
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
